鲁抗医药
(600789)
| 流通市值：77.09亿 | | | 总市值：79.75亿 |
| 流通股本：10.10亿 | | | 总股本：10.45亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 3,237,764,932.37 | 1,616,445,518.8 | 5,766,115,536.79 | 4,624,350,443.62 |
| 营业总成本 | 3,074,854,999.75 | 1,540,488,548.05 | 5,618,182,381.98 | 4,428,403,914.86 |
| 其他经营收益 | | | | |
| 营业利润 | 155,509,611.19 | 66,132,553.4 | 160,572,041.23 | 190,331,396.54 |
| 利润总额 | 155,916,739.32 | 66,739,069.62 | 161,207,120.09 | 186,336,080.99 |
| 净利润 | 145,987,096.15 | 56,534,399.6 | 111,906,367.03 | 146,619,239.95 |
| 每股收益 | | | | |
| 其他综合收益 | 223,988.93 | -454,273.62 | -2,413,737.03 | -1,986,272.05 |
| 综合收益总额 | 146,211,085.08 | 56,080,125.98 | 109,492,630 | 144,632,967.9 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 4,789,121,863.69 | 4,826,535,675.5 | 4,950,854,868.24 | 3,814,446,929.58 |
| 非流动资产: | | | | |
| 非流动资产合计 | 5,063,596,290.37 | 5,056,569,310.57 | 5,083,196,201.07 | 5,001,920,232.85 |
| 资产总计 | 9,852,718,154.06 | 9,883,104,986.07 | 10,034,051,069.31 | 8,816,367,162.43 |
| 流动负债: | | | | |
| 流动负债合计 | 2,971,016,395.92 | 3,147,837,930.25 | 3,398,238,991.78 | 3,190,669,440.87 |
| 非流动负债: | | | | |
| 非流动负债合计 | 1,480,724,104.29 | 1,422,435,940.24 | 1,379,167,696.59 | 1,520,868,329.46 |
| 负债合计 | 4,451,740,500.21 | 4,570,273,870.49 | 4,777,406,688.37 | 4,711,537,770.33 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 5,253,363,724.1 | 5,167,566,195.43 | 5,114,660,477.08 | 3,957,023,996.46 |
| 股东权益合计 | 5,400,977,653.85 | 5,312,831,115.58 | 5,256,644,380.94 | 4,104,829,392.1 |
| 负债和股东权益合计 | 9,852,718,154.06 | 9,883,104,986.07 | 10,034,051,069.31 | 8,816,367,162.43 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 2,650,447,982.78 | 1,313,555,180.85 | 5,270,386,648.73 | 3,901,835,418.37 |
| 经营活动现金流出小计 | 2,291,648,327.53 | 1,149,432,101.54 | 4,572,212,799.71 | 3,595,892,858.79 |
| 经营活动产生的现金流量净额 | 358,799,655.25 | 164,123,079.31 | 698,173,849.02 | 305,942,559.58 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 18,812,647.71 | 18,812,647.71 | 105,391,311.22 | 94,701,901.7 |
| 投资活动现金流出小计 | 164,178,005.55 | 38,303,519.16 | 338,862,954.47 | 209,213,507.48 |
| 投资活动产生的现金流量净额 | -145,365,357.84 | -19,490,871.45 | -233,471,643.25 | -114,511,605.78 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 405,055,500 | 349,547,500 | 3,162,149,719.17 | 1,349,991,458.24 |
| 筹资活动现金流出小计 | 1,038,059,773.88 | 712,037,353.37 | 2,006,638,977.91 | 1,495,642,130.78 |
| 筹资活动产生的现金流量净额 | -633,004,273.88 | -362,489,853.37 | 1,155,510,741.26 | -145,650,672.54 |
| 汇率变动对现金及现金等价物的影响 | -8,523,397.07 | -5,283,354.81 | 2,244,815.3 | 4,725,522.79 |
| 现金及现金等价物净增加额 | -428,093,373.54 | -223,141,000.32 | 1,622,457,762.33 | 50,505,804.05 |
| 期末现金及现金等价物余额 | 1,690,065,580.76 | 1,895,017,953.98 | 2,118,158,954.3 | 546,206,996.02 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -428,093,373.54 | - | 1,622,457,762.33 | - |